Comparative Pharmacology
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus OGEN 625.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORGESTIMATE AND ETHINYL ESTRADIOL versus OGEN 625.
NORGESTIMATE AND ETHINYL ESTRADIOL vs OGEN .625
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol suppresses gonadotropin release via estrogen receptor; norgestimate is a progestin that inhibits ovulation and thickens cervical mucus.
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
One tablet (norgestimate 0.250 mg/ethinyl estradiol 0.035 mg) orally once daily for 21 consecutive days followed by 7 placebo tablets.
0.625 mg orally once daily
None Documented
None Documented
Norgestimate: ~21.3 hours (range 16-36 hours); active metabolite 17-deacetyl norgestimate: ~33.2 hours (range 22-45 hours). Ethinyl estradiol: ~17.1 hours (range 14-22 hours). Terminal half-life supports once-daily dosing; steady-state achieved within 10-14 days.
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
Urine (primarily as glucuronide and sulfate conjugates; ~50-60% of dose), feces (~30-40% of dose as metabolites), minimal unchanged drug in urine
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Category D/X
Category C
Estrogen
Estrogen